Kaletra (Lopinavir/Ritonavir)
Kaletra (Lopinavir/Ritonavir or LPV/RTV) is a protease inhibitor used to treat HIV/AIDS. It is no longer listed in the HHS HIV Treatment Guidelines as a recommended regimen.
Adult Single Dose*: Take 400/100 mg (two 200/50-mg tablets or 5-mL oral solution) twice daily Each tablet contains 400 mg lopinavir and 200 mg ritonavir.
Restrictions:
- Oral solution must be take with food.
- Always take Kaletra in compination with other anti-HIV medicines.
- Women should not breastfeed while on Kaletra.
* This recommendation is for patients starting HIV treatment. A different dose is recommended for treatment experienced patients.
The Basics
- Patient Information About Kaletra (Lopinavir/Ritonavir) Tablets and Oral Solution (PDF) (October 2017)
From AbbVie Inc.
 An Overview of Kaletra (Lopinavir/Ritonavir) (August 8, 2017)
From AIDSinfo
- Lopinavir + Ritonavir (Kaletra) (November 30, 2012)
To read PDF, click here.
From AIDS InfoNet
- Kaletra (March/April 2012)
To read PDF, click here.
In Positively Aware, from Positively Aware
- FAQs About Kaletra (Lopinavir/Ritonavir) (January 12, 2012)
From The Body's "Ask the Experts" Forums
- Medication Guide for Kaletra (February 2011)
Created by the makers of Kaletra specifically for people with HIV. Includes a rundown of possible side effects, reasons why Kaletra may not be a good fit for everybody, meds to avoid while taking Kaletra, and tips on how to maximize the chances Kaletra will work well.
From Abbott Laboratories
- Patient Frequently Asked Questions (2011)
Information about the new Kaletra (lopinavir/ritonavir) tablets.
From Abbott Laboratories
- Kaletra (Lopinavir/Ritonavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Lopinavir (Kaletra) (August 15, 2006)
From AIDS Treatment Data Network
- Kaletra (Lopinavir/Ritonavir) (November 2005)
To read PDF, click here.
From The Center for AIDS Information & Advocacy
VIEW ALL ARTICLES
News
 Lopinavir/Ritonavir Pellets for Children Tentatively Approved by the FDA (June 2015)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Abbott Cuts Cost of AIDS Drug for Government Programs (May 10, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from CDC National Prevention Information Network
- Abbott Cuts Cost of AIDS Drug for Government Programs (April 29, 2011)
In Chicago Tribune
- Lopinavir/r Oral Solution (March/April 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- U.S. Jury Rejects Glaxo Antitrust Claim vs. Abbott (March 31, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from CDC National Prevention Information Network
- U.S. Warns Against Abbott HIV Drug in Premature Babies (March 9, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from CDC National Prevention Information Network
- Kaletra (Lopinavir/Ritonavir) Oral Solution Label Changes Related to Toxicity in Preterm Neonates (February 24, 2011)
From U.S. Food and Drug Administration
- Once a Day Kaletra Gets Approved for Treatment Experienced, but With Caution (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Indian Government Rejects Abbott's Patent Application for Second-Line ARV (January 4, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Lopinavir/Ritonavir Approved (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
VIEW ALL ARTICLES
Research
 This Week in HIV Research: Looking Forward, Looking Back (December 22, 2017)
From TheBodyPRO
 Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study (February 23, 2017)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
 Slow But Steady Increase in Kidney Risk Observed With TDF, Atazanavir, Lopinavir (August 24, 2016)
From TheBodyPRO
 Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results (March 24, 2015)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Outcomes in Infants Exposed to Lopinavir/Ritonavir in Utero (February 2014)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Kaletra + Raltegravir: Does Sparing Some Nukes Help Bones? (February 2014)
In TreatmentUpdate, from Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
 Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy (October 28, 2013)
In The 14th European AIDS Conference (EACS 2013), from TheBodyPRO
- Dual Therapy With Kaletra + Lamivudine Works Well Regardless of Viral Load (October 19, 2013)
From HIVandHepatitis.com
- Lopinavir/Ritonavir Monotherapy: The Answer's Still No (August 28, 2013)
In The 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO
- Lower-Dose Lopinavir/Ritonavir Reduces Side-Effects, Maintains Viral Control in Thai Children (July 9, 2013)
From aidsmap.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
